Multiple sclerosis future or investigational therapies

Jump to navigation Jump to search

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis future or investigational therapies

CDC on Multiple sclerosis future or investigational therapies

Multiple sclerosis future or investigational therapies in the news

Blogs on Multiple sclerosis future or investigational therapies

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

Therapies Under Investigation

A number of treatments that may curtail attacks or improve function are under investigation. Some of these treatments involve the combination of drugs that are already in use for multiple sclerosis, such as the joint administration of mitoxantrone and glatiramer acetate (Copaxone).[1] However, most treatments already in clinical trials involve drugs that are used in other diseases. These are alemtuzumab (trade name Campath),[2] daclizumab (trade name Zenapax),[3] inosine,[4]BG00012,[5] fingolimod,[6] and teriflunomide, the active metabolite of the DMARD leflunomide. Alemtuzumab performed better than interferon beta-1a in relapsing-remitting MS reducing disability, imaging abnormalities and frequence of relapses, at the cost of increased autoimmunity problems. These included three cases of thrombocytopenic purpura which led to the suspension of the therapy.[7]

Other drugs in clinical trials have been designed specifically for MS, such as laquinimod,[8] and Neurovax.[9]

Low dose naltrexone has been prescribed off-label for certain autoimmune disorders, including MS, and there is anecdotal evidence of benefit,[10][11] but only two small clinical trials have been conducted (as on December 2008), one in San Francisco, USA,[12] the other for the primary progressive variety in Milan, Italy.[13]

References

  1. United Kingdom early Mitoxantrone Copaxone trial. Onyx Healthcare (2006-01-01). Retrieved on 2007-09-02.
  2. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN. Genzyme (2007-02-01). Retrieved on 2007-09-02.
  3. Daclizumab. PDL Biopharma (2006-01-01). Retrieved on 2007-09-02.
  4. Treatment of Multiple Sclerosis Using Over the Counter Inosine. ClinicalTrials.gov (2006-03-16). Retrieved on 2007-09-02.
  5. Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2007-09-01). Retrieved on 2007-11-12.
  6. Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2006-02-09). Retrieved on 2007-09-02.
  7. The CAMMS223 Trial Investigators (2008). "Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis". N Engl J Med. 359 (17): 1786–1801. PMID 18946064.
  8. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005). "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS". Neurology. 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
  9. Darlington CL (2005). "Technology evaluation: NeuroVax, Immune Response Corp". Curr. Opin. Mol. Ther. 7 (6): 598–603. PMID 16370383.
  10. Agrawal YP (2005). "Low dose naltrexone therapy in multiple sclerosis". Med. Hypotheses. 64 (4): 721–4. doi:10.1016/j.mehy.2004.09.024. PMID 15694688.
  11. search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis
  12. 2007 clinical trial using LDN
  13. Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G (2008). "A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis". Multiple Sclerosis. 14 (8): 1076–83. PMID 18728058.


Template:WH Template:WS